Italia markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
4,2100-0,1700 (-3,88%)
Alla chiusura: 04:00PM EDT
4,1996 -0,01 (-0,25%)
Dopo ore: 05:14PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente4,3800
Aperto4,3700
Denaro4,1800 x 300
Lettera4,2600 x 800
Min-Max giorno4,1800 - 4,4200
Intervallo di 52 settimane4,1800 - 9,0700
Volume3.808.518
Media Volume3.140.872
Capitalizzazione867,892M
Beta (5 anni mensile)1,93
Rapporto PE (ttm)N/D
EPS (ttm)-1,1800
Prossima data utili06 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A13,82
  • GlobeNewswire

    BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 23 newly-hired employees stock options to purchase an aggregate of 128,800 shares, and restricted stock units (RSUs) covering an aggregate of 88,650 shares, of BioCryst common stock. The options and RSUs were granted as of September 29, 2023, as inducements material to each employee entering into emp

  • GlobeNewswire

    INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

    INTENDED FOR CANADIAN AUDIENCES ONLYRESEARCH TRIANGLE PARK, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Institut national d'excellence en santé et services sociaux (INESSS) has issued a positive recommendation for PrORLADEYO® (berotralstat) to be reimbursed for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age and older in Quebec. “While much progress has been made on behalf o

  • GlobeNewswire

    BioCryst to Present at Upcoming Investor Conferences

    RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6th in Boston at 3:00 p.m. ET and the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13th in New York at 12:30 p.m. ET. Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of Bi